First recommendation for inclusion in the authorisation list
The REACH Regulation requires that ECHA identifies from the "Candidate List" priority substances to be included in Annex XIV of REACH (the "Authorisation List") and recommends Annex XIV entries (i.e. transitional arrangements and, where relevant, exemptions and review periods) for these substances to the European Commission, taking into account the opinion of the Member State Committee. The European Commission finally decides, by "comitology" procedure (with scrutiny), which substances will be included in Annex XIV and with which entries.
ECHA will make recommendations at least every second year.
ECHA's Annex XIV Recommendations:
In addition to its recommendation, ECHA provided the European Commission with several background documents which give more details and justifications for the prioritisation and, where relevant, the recommendation for Annex XIV entries.
General approach documents:
- General approach for Prioritisation of Substances of Very High Concern (SVHCs) for Inclusion in the List of Substances Subject to Authorisation: this document describes the general approach taken by ECHA for prioritising the substances that are listed on the present list of candidate substances for inclusion in Annex XIV (the "Candidate List")
- General approach for defining the Annex XIV entries: this document describes the general approach taken by ECHA for developing its draft Annex XIV entries (e.g. application and sunset dates, exemptions for certain uses) for the substances which have been prioritised.
|Substance Name||EC Number||CAS Number||Link to ECHA's background document 1|
|5-tert-butyl-2,4,6-trinitro-m-xylene (Musk xylene)||201-329-4||81-15-2|
|Alkanes, C10-13, chloro (Short Chain Chlorinated Paraffins - SCCPs)||287-476-5||85535-84-8|
|Benzyl butyl phthalate (BBP)||201-622-7||85-68-7|
|Bis(2-ethylhexyl) phthalate (DEHP)||204-211-0||117-81-7|
|Dibutyl phthalate (DBP)||201-557-4||84-74-2|
|Hexabromocyclododecane HBCDD), and all major diastereoisomers identified, i.e.: alpha-, beta- and gamma- hexabromocyclododecane||247-148-4 and 221-695-9||25637-99-4 3194-55-6 (134237-50-6) (134237-51-7) (134237-52-8)|
1 These updated background documents are based on "(ECHA's) Prioritisation and Annex XIV Background information" and "Justification for the Draft Recommendation of Inclusion in Annex XIV" as developed by ECHA for each substance and published on ECHA's website on 14 January 2009 in the framework of the public consultation on the priority setting and the draft recommendation (see "Further information")
2 These documents have been developed by external contractors for ECHA; they have not been updated on the basis